Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) CEO Faraz Ali sold 14,533 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $1.25, for a total value of $18,166.25. Following the completion of the sale, the chief executive officer owned 302,792 shares in the company, valued at $378,490. The trade was a 4.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Tenaya Therapeutics Trading Up 8.6%
Shares of NASDAQ:TNYA traded up $0.10 during trading on Monday, hitting $1.26. 19,041,941 shares of the company were exchanged, compared to its average volume of 2,561,319. The stock has a market cap of $205.35 million, a price-to-earnings ratio of -1.31 and a beta of 3.01. Tenaya Therapeutics, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $4.01. The firm has a fifty day moving average price of $0.71 and a two-hundred day moving average price of $0.66.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. As a group, research analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.
Analyst Upgrades and Downgrades
TNYA has been the topic of several research reports. Chardan Capital restated a "buy" rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, August 7th. Wall Street Zen raised Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $6.25.
Get Our Latest Stock Report on TNYA
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in TNYA. DAFNA Capital Management LLC acquired a new position in shares of Tenaya Therapeutics during the 1st quarter worth approximately $27,000. Woodline Partners LP acquired a new position in shares of Tenaya Therapeutics during the 4th quarter worth approximately $28,000. Commerce Bank acquired a new position in shares of Tenaya Therapeutics during the 4th quarter worth approximately $29,000. Mariner LLC acquired a new position in shares of Tenaya Therapeutics during the 4th quarter worth approximately $30,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Tenaya Therapeutics during the 4th quarter worth approximately $32,000. 90.54% of the stock is owned by institutional investors and hedge funds.
Tenaya Therapeutics Company Profile
(
Get Free Report)
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access